ClinConnect ClinConnect Logo
Search / Trial NCT06305156

Protocol Optimization in CT for the Quantification of BMD

Launched by HATEM ALKADHI · Mar 7, 2024

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at how well a new type of CT scan, called photon-counting CT, measures bone mineral density (BMD) compared to a traditional method known as DXA scanning. Bone mineral density is important for diagnosing conditions like osteoporosis and osteopenia, which are related to weak bones. The goal of the study is to see if the new CT scan can provide accurate measurements of BMD and to find ways to improve how these scans are done.

To participate in this trial, individuals must be between the ages of 65 and 74 and have a doctor's referral for a CT scan that includes the lower back area. Participants will need to give their consent and may require an interpreter if they speak a different language. If chosen for the study, they will have a CT scan on the same day as their regular appointment and a separate appointment for the DXA scan. It’s important to know that certain conditions, such as being pregnant or having specific medical issues, may prevent someone from participating. Overall, this trial aims to improve the way we measure bone health to better help patients at risk of fractures.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Informed Consent signed by the subject
  • Referral to a regular clinically indicated CT examination covering the lumbar area (e.g., Abdomen, Thorax + Abdomen, Neck + Thorax +Abdomen)
  • Informed written and oral consent (interpreter present in case of foreign language patients)
  • No contraindication to the clinically indicated CT examination
  • Exclusion Criteria:
  • Patients \< 18 years
  • Pregnant women
  • Vulnerable subjects
  • Contraindications to the clinically indicated CT scan
  • Multiple Myeloma
  • Diffuse bone metastasis
  • Fixateur interne in the lumbar spine
  • Kyphoplasty in the lumbar spine
  • Enterally administrated contrast agent
  • Obtaining informed consent is not possible
  • Withdrawal of consent orally or in writing
  • Inability to follow the procedures of the investigation, e.g., due to language problems, psychological disorders, dementia, etc. of the subject
  • Immobility (patients confined to a wheelchair or to bed)

About Hatem Alkadhi

Hatem Alkadhi is a dedicated clinical trial sponsor known for advancing medical research through innovative study designs and a commitment to ethical standards. With a focus on enhancing patient outcomes, Alkadhi leads initiatives that explore novel therapeutic approaches across various therapeutic areas. By fostering collaboration among healthcare professionals, researchers, and regulatory bodies, he aims to ensure the integrity and efficiency of clinical trials while prioritizing participant safety and compliance with regulatory requirements. His expertise and leadership in the clinical research landscape contribute significantly to the development of effective treatments and the progression of medical science.

Locations

Zürich, , Switzerland

Patients applied

0 patients applied

Trial Officials

Hatem Alkadhi, MD, MPH

Principal Investigator

Diagnostic and Interventional Radiology, University Hospital Zurich

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported